[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Great questions on depression", "description": "Thanks to Neil Oliver and GB news for an excellent series of questions with massive implications for good health and health care.", "link": "https://www.youtube.com/watch?v=nlmWDm8cRxw", "date_published": "2022-08-20 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "New covid vaccine for UK", "description": "Bivalent new vaccine, Moderna press release\n\nhttps://investors.modernatx.com/news/news-details/2022/Moderna-Announces-Omicron-Containing-Bivalent-Booster-Candidate-mRNA-1273.214-Demonstrates-Superior-Antibody-Response-Against-Omicron/default.aspx\n\n\nOmicron-containing bivalent COVID booster candidate, mRNA-1273.214\n\n(original mRNA-1273 vaccine),\n\nSuperior neutralizing antibody response\n\nin baseline seronegative participants. \n\nincreased neutralizing geometric mean titers (GMT) against Omicron approximately 8-fold above baseline levels. \n\nmRNA-1273.214 50 \u03bcg booster dose, well-tolerated in the 437 study participants\n\nThe safety and reactogenicity profile of the mRNA-1273.214 50 \u03bcg booster dose was similar to that of mRNA-1273 50 \u03bcg\n\nBA.1\n\nSARS-CoV-2 variants of concern and variants under investigation in England \n\nTechnical briefing 44 \n\nhttps://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1093275/covid-technical-briefing-44-22-july-2022.pdf\n\nBA.2  3.4% \n\nBA.4  17.2% \n\nBA.5  78.7%\n\nOther 0.7%\n\nUS variants\n\nhttps://covid.cdc.gov/covid-data-tracker/#variant-proportions\n\nBA.5  88.8%\n\nBA.4  5.3%\n\nBA.4.6 5.1%\n\nBA.2.12.1 0.8%\n\nBA.2  0%\n\nBA.1s 0%\n\nDelta 0%\n\nEpidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada\n\nhttps://jamanetwork.com/journals/jamanetworkopen/fullarticle/2793551\n\nPopulation-based cohort study of 297 individuals in Ontario, Canada,\n\nwith myocarditis or pericarditis following COVID-19 vaccination,\n\nfound higher rates of myocarditis or pericarditis associated with receipt of mRNA-1273 compared with BNT162b2 as a second dose, \n\nparticularly among male individuals aged 18 to 24 years. \n\nThe results suggest that there may be product-specific differences in rates of myocarditis or pericarditis after receiving mRNA vaccines\n\nFirst bivalent COVID-19 booster vaccine approved by UK medicines regulator\n\nhttps://www.gov.uk/government/news/first-bivalent-covid-19-booster-vaccine-approved-by-uk-medicines-regulator\n\nModerna bivalent approved for adult booster doses by MHRA\n\nSpikevax bivalent Original/Omicron\n\n25 micrograms targets the original virus strain\n\n25 micrograms targets Omicron\n\nOmicron (BA.1) and the original 2020 strain\n\n(was also found to generate a good immune response against BA.4 and BA.5)\n\nSafety monitoring\n\nside effects observed were the same as those seen for the original Moderna booster dose,\n\nand were typically mild and self-resolving, \n\nand no serious safety concerns were identified.\n\nGlobal covid deaths\n\nhttps://www.worldometers.info/coronavirus/\n\n6,466,947\n\nEvidence cited by HMRA\n\nhttps://www.thelancet.com/journals/laninf/article/PIIS1473-3099%2822%2900320-6/fulltext\n\nBased on official reported COVID-19 deaths, \n\nwe estimated that vaccinations prevented 14\u00b74 million deaths from COVID-19 in 185 countries,\n\nbetween Dec 8, 2020, and Dec 8, 2021. \n\n19\u00b78 million when we used excess deaths as an estimate\n\nJoint Committee on Vaccination and Immunisation (JCVI) updated statement on the COVID-19 vaccination programme for autumn 2022\n\nFor autumn 2022\n\nhttps://www.gov.uk/government/publications/jcvi-updated-statement-on-the-covid-19-vaccination-programme-for-autumn-2022/joint-committee-on-vaccination-and-immunisation-jcvi-updated-statement-on-the-covid-19-vaccination-programme-for-autumn-2022\n\nJCVI advises\n\nthe following groups should be offered a COVID-19 booster vaccine:\n\nresidents in a care home for older adults and staff working in care homes for older adults\n\nfrontline health and social care workers\n\nall adults aged 50 years and over\n\npersons aged 5 to 49 years in a clinical risk group\n \npersons aged 5 to 49 years who are household contacts of people with immunosuppression\n\npersons aged 16 to 49 years who are carers\n \nTime to collect PROSPECTIVE data\n\n\nCardiovascular Effects of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents\n\nhttps://www.preprints.org/manuscript/202208.0151/v1\n\nThai adolescents, 13 to 18, both sexes \n\nCardiovascular effects\n\nFound in 29.24% of patients,\n\nMost common cardiovascular effects\n\nTachycardia, 7.64%\n\nShortness of breath, 6.64%\n\nPalpitation, 4.32%\n\nChest pain, 4.32%\n\nHypertension, 3.99%\n\nAbnormal ECG finding, 54 patients (17.94%) \n\nSeven participants (2.33%)\n\n(all male)\n\nAt least one elevated cardiac biomarker or positive lab assessments", "link": "https://www.youtube.com/watch?v=VZ1ppIXCOsU", "date_published": "2022-08-19 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]